David Khougazian announced as president of Sanofi Pasteur MSD
pharmafile | July 29, 2015 | Appointment | Business Services, Research and Development, Sales and Marketing | MSD, Merck, Sanofi Pasteur
Sanofi Pasteur and Merck have appointed David Khougazian as president of their joint company, Sanofi Pasteur MSD.
David Khougazian joined Sanofi Pasteur MSD in July and from September 1 will succeed Dr Jean-Paul Kress, who has led the company since July 2011. Kress will leave Sanofi Pasteur MSD to join the Sanofi group.
David Khougazian is an engineer who holds an MBA. Since 2011 David has served as Sanofi chief of staff, working closely with the chief executive and the Sanofi executive committee in transforming the company and delivering on its development agenda.
He assumed responsibility for various global strategic and organisational projects, supported the post-acquisition integration of Genzyme, and led the global health policy effort and managed interactions with multiple external stakeholders.
Olivier Charmeil, president and chief executive of Sanofi Pasteur, says: “David’s appointment marks a new phase in our development in Western Europe; a challenging and strategic region for our vaccines activity. His knowledge of European markets and external stakeholders will be a strong asset to grow Sanofi Pasteur MSD’s position in Europe.”
“David’s leadership skills and expertise in global strategy and health policy make him uniquely suited to lead Sanofi Pasteur MSD in Europe,” comments Jacques Cholat, President of Merck Vaccines. “His experience will help us to deliver important vaccines for the benefit of European populations.”
Related Content
Merck to acquire Curon Biopharmaceutical’s B-Cell Depletion Therapy
Merck have announced that they have entered into an agreement with private biotechnology company Curon …
Merck and Daiichi Sankyo expand development and commericalisation agreement to include MK-6070
Daiichi Sankyo and Merck (known as MSD outside of the US and Canada) have announced …
CHMP gives positive opinion for Merck’s KEYTRUDA for unresectable or metastatic urothelial carcinoma
Merck (known as MSD outside of the US and Canada) has announced that its anti-PD-1 …
